Furthermore, studies have indicated that the combination of TFRC-targeting agents with existing chemotherapy regimens can enhance the overall efficacy of treatment, particularly in resistant cancer types such as breast and prostate cancer (27, 37). This evidence concerns the gene TFRC and prostate carcinoma.